PSYCHOPHARMACOLOGY OF ADOLESCENTS WITH AUD AND ADHD

申请人的摘要：这一建议的中期职业生涯研究者奖， 以病人为导向的研究（K-24）描述了一个以病人为导向的计划， 临床试验领域的研究、指导和职业发展 涉及患有酒精使用障碍（AUDS）和共病的青少年 注意力缺陷多动障碍（ADHD）和其他精神病理学。 导师计划包括有组织的，结构化的招聘工作， 适当的受训人员，包括儿童和青少年精神病医生， 参与和发展具体的培训经验， 这些实习生。 拟议的职业发展计划包括课程工作和 监督与临床试验相关的方法学和统计学， ADHD和AUDS青少年的精神药理学。 协助双方的职业生涯 开发和指导工作，此应用程序包括一个建议， 安非他酮缓释剂（SR）的双盲、安慰剂对照研究 患有AUD和ADHD共病的青少年。 该研究的具体目的是比较安非他酮SR与 安慰剂治疗合并AUD和ADHD的青少年ADHD 症状，饮酒和其他物质使用行为。 很少有 研究已经检查了这种共病的药物治疗 人口 由于精神兴奋剂对青少年存在潜在风险， 由于滥用或转移而合并AUD/ADHD，需要使用其他药物 考虑了 将从社区招募100名14-18岁的青少年 治疗方案。 筛选、知情同意和基线评估后 为了确认AUD和当前ADHD的诊断，青少年将被 随机分为两组，分别接受安慰剂或安非他酮缓释剂 （滴定至300 mg/天的剂量）。 在为期16周的试验期间，每周或 每两周一次的随访评估将评估ADHD和AUD的疗效 药理学和安全性。 本研究的结果和实施，沿着 有组织、有结构的指导活动和先进的 在临床试验的技能，将有助于推进申请人的长期 进行药理学和多模式临床试验的目标， 患有AUD或物质使用障碍（SUDS）和共病的青少年 精神疾病 它还将为指导提供机会， 实习生和初级同事。 这些补充努力将推动 通过研究和培训。

APPLICANT'S ABSTRACT: This proposal for a Mid-Career Investigator Award in Patient-Oriented Research (K-24) describes a plan in patient-oriented research, mentor ship and career development in the area of clinical trials involving adolescents with alcohol use disorders (AUDS) and comorbid attention-deficit hyperactivity disorder (ADHD) and other psychopathology. The mentor ship plan includes organized, structured efforts in recruiting appropriate trainees, including child and adolescent psychiatrists, for mentor ship and involvement and development of specific training experiences for these trainees. The proposed career development plan includes course work and supervision in methodology and statistics related to clinical trials and psychopharmacology in adolescents with ADHD and AUDS. To assist both career development and mentor ship efforts, this application includes a proposal for a double-blind, placebo-controlled study of bupropion Sustained Release (SR) in adolescents with comorbid AUD and ADHD. The specific aim of the study is to compare the efficacy of bupropion SR vs. placebo in the treatment of adolescents with comorbid AUD and ADHD for ADHD symptoms, drinking and other substance use behaviors. There have been few studies that have examined pharmacological treatment in this comorbid population. As psycho stimulants present a potential risk to adolescents with comorbid AUD/ADHD due to abuse or diversion, other medications need to be considered. One hundred (100) adolescents, ages 14-18, will be recruited from community treatment programs. After screening, informed consent and baseline assessment to confirm diagnoses of an AUD and current ADHD, the adolescents will be randomized into two groups, which will receive either placebo or bupropion SR (titrated to a dose of 300 mg/day). During the 16-week trial, weekly or bi-weekly follow-up assessments will assess efficacy for both ADHD and AUD symptomatology and safety. The results and conduct of this study, along with organized, structured mentor ship activities and the development of advanced skills in clinical trials, will serve to advance the applicant's long-term goals of conducting both pharmacological and multi-modal clinical trials in adolescents with AUDs or Substance Use Disorders (SUDS) and comorbid psychiatric disorders. It will also provide opportunities for mentor ship to trainees and junior colleagues. These complementary efforts will advance the field through both research and training.